Ikegawa Shuntaro, Doki Noriko, Kurosawa Shuhei, Yamaguchi Tsukasa, Sakaguchi Masahiro, Harada Kaito, Yamamoto Keita, Hino Yutaro, Shingai Naoki, Senoo Yasushi, Hattori Keiichiro, Igarashi Aiko, Najima Yuho, Kobayashi Takeshi, Kakihana Kazuhiko, Sakamaki Hisashi, Haraguchi Kyoko, Okuyama Yoshiki, Ohashi Kazuteru
a Division of Hematology , Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital , Tokyo , Japan ;
b Division of Transfusion and Cell Therapy , Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital , Tokyo , Japan.
Leuk Lymphoma. 2016;57(6):1375-81. doi: 10.3109/10428194.2015.1099644. Epub 2015 Dec 23.
Recent studies have shown that CD25 expression at the time of diagnosis of acute myeloid leukemia (AML) may be associated with an unfavorable outcome. We focus on patients with AML without complete remission (CR) and examine the clinical correlation between surface CD25 expression at the time of transplant and subsequent transplant outcomes. We observed a significant difference in overall survival (OS), disease-free survival (DFS) and cumulative incidence of relapse (CIR) between CD25 positive (+) (n = 22) and negative (-) groups (n = 44) (2-year OS; CD25 (+) group: 5% vs. CD25 (-) group: 40%, p < 0.0001, 2-year DFS; 5% vs. 29%, p < 0.0001, 2-year CIR; 77% vs. 52%, p = 0.03). Multivariate analysis showed that CD25 expression was an independent adverse factor for OS (p = 0.002) and relapse (p = 0.001). Patients with AML with residual CD25 positive blasts at the time of transplant may require additional therapy before or after transplant to improve survival.
最近的研究表明，急性髓系白血病（AML）诊断时的CD25表达可能与不良预后相关。我们聚焦于未完全缓解（CR）的AML患者，并研究移植时表面CD25表达与后续移植结局之间的临床相关性。我们观察到CD25阳性（+）组（n = 22）和阴性（-）组（n = 44）在总生存期（OS）、无病生存期（DFS）和复发累积发生率（CIR）方面存在显著差异（2年OS；CD25（+）组：5% 对 CD25（-）组：40%，p < 0.0001，2年DFS；5% 对 29%，p < 0.0001，2年CIR；77% 对 52%，p = 0.03）。多变量分析显示，CD25表达是OS（p = 0.002）和复发（p = 0.001）的独立不良因素。移植时AML残留CD25阳性原始细胞的患者可能需要在移植前或移植后进行额外治疗以提高生存率。
